Nationwide Children’s Hospital Dedicated to Life-saving Gene Therapies
Healthcare innovation in Columbus
It is excellent to see a local leader featured in this inspiring Xconomy story about Nationwide Children’s Hospital’s brave commitment to healthcare innovation and saving children’s lives by researching, testing, and spinning out promising gene therapies.
This quote from Xconomy says it all:
“Thanks to ambitious officials, a risk-taking administration, and a tight connection between its labs and its hospital practice, Nationwide has become a gene therapy leader.” — Ben Fidler, Xconomy
At Rev1, we see healthcare innovation first-hand the incredible dedication of the scientists and entrepreneurs from the Columbus region who are mentioned in the article.
Rev1 manages the NCH Fund I, which focuses on Nationwide Children’s Hospital spinouts as well as the Catalyst Fund, which includes investments from The Ohio State University, Nationwide Children’s Hospital, Ohio Third Frontier, and Rev1 Ventures. Two of the companies mentioned in this article, Celenex (Acquired by Amicus Therapeutics) and Myonexus Therapeutics (acquired by Sarepta).
We celebrate their persistence and groundbreaking discoveries.
Read the entire Xconomy article.
